DTcP

Phase 3Biologic

CanSino Biologics Inc.

DTcP is one of 6 biologic programs targeting Diphtheria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DiphtheriaActive, not recruiting

DiphtheriaPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Diphtheria

#DrugCompanyPhaseTrials

BCG Vaccine

GGynecologic Oncology Group

Phase 3

1 2

Dtacp

CChangchun BCHT Biotechnology Co.

Phase 3

2 3

DTcP

CanSino Biologics Inc.

Phase 3

1 4

Tdap Vaccine

Sanofi

Phase 1

1 5

Pentavalent Vaccine

GSK

Preclinical

2 6

PPV23

CanSino Biologics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diphtheria1 trial

A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)

Active, not recruiting· CanSino Biologics Inc. logo

CanSino Biologics Inc.·Phase 3·NCT05951725·2,520 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DTcP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DTcP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DTcP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CanSino Biologics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CanSino Biologics Inc.

DTcP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diphtheria1 trial

References

Drug Info

Quick Facts

Related News